logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Blueprint Medicines Corporation


USPTO Granted Patents = 60



Trademarks = 8

Forward Citations = 779

Loading Chart...
Loading Chart...

42 inventors (with patents filed for the assignee):

goldMedal Joseph L Kim (35 out of 60 patents)

silverMedal Douglas Wilson (19 out of 30 patents)

bronzeMedal Chandrasekhar V Miduturu (19 out of 21 patents)

4.  Brian Lewis Hodous (19 out of 43 patents)

5.  Kevin J Wilson (17 out of 40 patents)

6.  Jason D Brubaker (15 out of 45 patents)

7.  Lucian V DiPietro (13 out of 24 patents)

8.  Neil Bifulco (13 out of 17 patents)

9.  Natasja Brooijmans (13 out of 13 patents)

10.  Yulian Zhang (12 out of 30 patents)

11.  Steven Mark Wenglowsky (10 out of 10 patents)

12.  Nicolas Stransky (9 out of 9 patents)

13.  Emanuele Perola (7 out of 42 patents)

14.  Thomas A Dineen (7 out of 7 patents)

15.  Paul E Fleming (6 out of 32 patents)


Core Competencies:
Wild Type Kit Inhibitors
Dosing Regimens
MAP4K1 Inhibitors
EGFR Inhibitors
Crystalline Forms
CDK2 Inhibitors
RET Inhibitors
Activin Receptor-Like Kinase
NTRK Disorders
Fibroblast Growth Factor Receptor
Substituted Pyrrolopyridines
Compounds for KIT Disorders

60 patents:

1. 12448379 - Wild type kit inhibitors (2025-10-21),
2. 12252494 - Dosing regimens of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine for treatment of indolent systemic mastocytosis (2025-03-18),
3. 12202844 - MAP4K1 inhibitors (2025-01-21),
4. 12172983 - EGFR inhibitors (2024-12-24),
5. 12060354 - Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making (2024-08-13),
6. 12042495 - MAP4K1 inhibitors (2024-07-23),
7. 11999744 - Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making (2024-06-04),
8. 11970498 - CDK2 inhibitors (2024-04-30),
9. 11964980 - Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making (2024-04-23),
10. 11932648 - CDK2 inhibitors (2024-03-19),
11. 11872192 - RET inhibitor for use in treating cancer having a RET alteration (2024-01-16),
12. 11827642 - Compositions useful for treating disorders related to KIT (2023-11-28),
13. 11718602 - EGFR inhibitors (2023-08-08),
14. 11634422 - Inhibitors of activin receptor-like kinase (2023-04-25),
15. 11534441 - MAP4K1 inhibitors (2022-12-27),
Blueprint Medicines is a precision therapy company focused on genomically defined cancers, rare diseases, and cancer immunotherapy. The company develops and commercializes targeted therapies to address patients' needs. Through its precision medicine approach, Blueprint Medicines aims to improve outcomes and quality of life for patients.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

...
60 Patents

#38 in Cambridge, MA

#330 in Massachusetts

#5,818 in US

#11,784 in the World

...
Cambridge, MA, United States of America

Blueprint Medicines Corporation

Forward Citations = 779

42 inventors:

goldMedal Joseph L Kim (35 out of 60 patents)

silverMedal Douglas Wilson (19 out of 30 patents)

bronzeMedal Chandrasekhar V Miduturu (19 out of 21 patents)

4.  Brian Lewis Hodous (19 out of 43 patents)

5.  Kevin J Wilson (17 out of 40 patents)

Please report any incorrect information to support@idiyas.com
Loading…